<DOC>
	<DOCNO>NCT02651155</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety oral administration lubiprostone 24 μg twice daily ( BID ) 4 week participant chronic idiopathic constipation ( CIC ) compare placebo .</brief_summary>
	<brief_title>Lubiprostone Treatment Chronic Idiopathic Constipation</brief_title>
	<detailed_description>The drug test study call lubiprostone . Lubiprostone test treat people chronic idiopathic constipation . This study look frequency spontaneous bowel movement ( SBMs ) people take lubiprostone compare placebo . The study enroll approximately 204 patient . Participants randomly assign ( chance , like flip coin ) one two treatment group , equal number subject treatment group—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Lubiprostone 24 μg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient All participants ask take one capsule breakfast one capsule dinner day throughout study . All participant ask record time SBM detail SBM ( include consistency stool difficulty pass ) diary . This multi-center trial conduct Russia . The overall time participate study 8 week . Participants make multiple visit clinic , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>1 . In opinion investigator , capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has history constipation define spontaneous bowel movement ( SBM ) frequency le 3 time per week average 6 month longer SBM frequency observe Screening Period . 4 . Has 1 symptom associate SBM ( describe ) 6 month longer start Screening : 1 . Scybalum stool hard feces least 1 every4 bowel movement . 2 . Sensation incomplete evacuation least 1 every 4 bowel movement . 3 . Straining least 1 every 4 bowel movement . 5 . Rarely loose stool without use laxative . 6 . Is willing able keep diary his/her willing able complete questionnaire . 7 . Is male female age 18 year old , time signing informed consent . 8 . A female participant childbearing potential sexually active agrees use routinely adequate contraception signing inform consent throughout duration study 14 day last dose study drug . 1 . Has receive investigational compound within 30 day prior Screening . 2 . Has receive lubiprostone previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has , judgment investigator , clinically significant abnormal hematological parameter hemoglobin , hematocrit , erythrocytes Screening . 5 . Has history clinical manifestation significant mechanical obstruction ( intestinal obstruction due tumor , hernia etc ) . 6 . Has history hypersensitivity allergies lubiprostone excipients . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening Visit . 8 . Is required take exclude medication . 9 . If female , pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 10 . Participant whose constipation consider due drug prohibit concomitant medication administer . 11 . Is chronic constipation due secondary cause ( medication , diabetes mellitus , hypothyroidism , depression , etc . ) 12 . Has sufficient criterion irritable bowel syndrome ( IBS ) functional defecation disorder . 13 . SBM frequency 3 per week . 14 . SBM frequency le 3 time per week le 6 month duration whose symptom associate SBM present less 6 month ( hard feces , sensation incomplete evacuation , strain ) . 15 . Received treatment rescue medication within 24 hour prior first dose morning Day1 : bisacodyl suppository , standard laxative , glycerin enema , rescue medication . 16 . Has megacolon/megarectum receive diagnosis intestinal pseudoobstruction . 17 . Has confirm suspect organic disorder large intestine ( obstruction , stenosis , carcinoma , inflammatory bowel disease ) . Organic disorder large intestine confirm rule use result enema Xray examination total colonoscopy perform previous 2 year . If participant history show current evidence weight loss , anemia , rectal bleeding , organic disorder may rule base result test perform past 3 year . Any participant total colonoscopy detect polyp require treatment exclude study .Note : Participant screen unless least 7 day pass since enema Xray examination , total colonoscopy sigmoidoscopy perform . 18 . Has hospitalize gastrointestinal abdominal surgery within 3 month prior Screening . 19 . Has significant cardiovascular , liver , lung , kidney , neurological , mental disease ( include exist alcohol drug abuse problem ) systemic disease . 20 . Has significant clinical finding significant abnormality find hematology test , serum chemistry , urinalysis . 21 . Participant noncompliance study protocol ( administration schedule , visit schedule , diary completion study procedure ) expect . 22 . Has history malignant disease ( except basal cell carcinoma ) within 5 year prior Screening . 23 . Has screen abnormal laboratory value suggest clinically significant underlying disease condition may prevent participant enter study ; participant : creatinine &gt; 1.5 mg/dL , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ULN ) , total bilirubin &gt; 2.0 mg/dL AST/ALT elevate limit normal value . 24 . Participant investigator/subinvestigator determine ineligible participate study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>